NCT03951272Unknown不适用
A Prospective, Multi-center, Randomized, Parallel-controlled Clinical Trial Evaluating the Efficacy and Safety of Lyoplant Onlay in Repairing Cerebral Dura Mater
B. Braun Medical International Trading Company Ltd.1 个研究点 分布在 1 个国家目标入组 240 人开始时间: 2018年7月24日最近更新:
适应症
干预措施
试验速览
- 阶段
- 不适用
- 发起方
- 入组人数
- 240
- 试验地点
- 1
- 主要终点
- Surgical successful rate without leakage of cerebrospinal fluid (CSF) 90 days
研究概览
简要总结
Objective of this clinical trial is to compare the safety and efficacy of Mianfengxing Kexishou Yingmo Bupian(Lyoplant® Onlay) and Yingmo Bupianfor dural repair.270 subjects will be enrolled for this study.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Treatment
- 盲法
- Single (Outcomes Assessor)
入排标准
- 年龄范围
- 18 Years 至 75 Years（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Surgical patients who will receive dura mater replacement in neurosurgery;
- •18 to 75 years old, either sexes;
- •Patients are ready and able to accept all visits during the trial.
- •Patients are willing and able to sign Informed Consent Form (ICF) to join this clinical trial.
- •Related to lesions:
- •Target lesion is cerebral and cerebellum dura mater defect closure, intracranial hypertension remission;
- •Surgical wound classification is Class I/sterile operation and risk index category (RIC) ≤ 2.
排除标准
- •Patients with local cerebral infection;
- •Patients who suffer from systemic infection (e.g. urinary tract infection (UTI), acquired pneumonia) or any infection sign at surgical site before the surgery, with body temperature > 38.5℃, positive result in blood culture, and/or positive result in chest X-ray examination;
- •Patients who are allergic to the equipment components (Such as, by asking the patient's history of allergies, doctors understand whether the patient is allergic to proteins of bovine origin or implant or not);
- •There is metal implant in patient's brain and the implant will interfere the assessment on devices or surgery recovery;
- •Patients in gestation period or lactation period or planned to be pregnant during the trial;
- •Patients with more than 1 separated dura mater defects;
- •Patients with previous neurosurgery history at the same anatomic site;
- •Patients with cranial open trauma;
- •Patients requiring the use of dura adhesive or sealant;
- •Patients whose expected survival time is less than 12 months;
- •Patients received chemotherapy and/or radiotherapy within 3 months before the surgery;
- •Patients who had diagnosed as malignant tumor of other parts except brain tumor, uncontrolled diabetes, septicemia, systemic collagen diseases clinically;
- •Patients who had been accompanied with liver and renal dysfunction, with ALT and AST>1.5 times the upper limit of the standard, total bilirubin level > 2.5 mg/dl, creatinine level > 2.0 mg/dl;
- •Patients with significant clinical coagulation disorders, Activated partial thromboplastin time (APTT) was 3 times more than ULN (upper limit of normal), international normalized ratio (INR) is ≥ 1.7, or under the treatment of Warfarin or Coumadin;
- •Patients with immune system damage or autoimmune diseases (white blood cell (WBC) count is < 4000/uL or >20,000/uL);
- •Patients whose serological test results show that people with hepatitis B, hepatitis C, syphilis, AIDS and other infectious diseases during screening period;
- •Patients in whom subdural drainage for more than 2 days must be performed in the surgery;
- •Patients who are participating other clinical trials of investigational devices/drugs;
- •Patients who are not suitable for this study as determined by the investigators.
研究组 & 干预措施
Lyoplant® Onlay
Experimental
All the model including 2.5cm×2.5cm, 5.0cm×5.0cm,2.5cm×7.5cm,7.5cm×7.5cm,10.0cm×12.5cm will be used in this study
干预措施: Lyoplant® Onlay/DURAFORM™ Dural Graft Implant (Device)
DURAFORM™ Dural Graft Implant
Active Comparator
All the model including 2.54cm×2.54cm,5.08cm×5.08cm, 2.54cm×7.62cm, 7.62cm×7.62cm,10.16cm×12.70cm will be used in this study
干预措施: Lyoplant® Onlay/DURAFORM™ Dural Graft Implant (Device)
结局指标
主要结局
Surgical successful rate without leakage of cerebrospinal fluid (CSF) 90 days
时间窗: 90days
Surgical successful rate without leakage of cerebrospinal fluid (CSF) 90 days after the surgery (Confirmed by radiological image evaluation and physical examination on surgical site). Each patient firstly undergoes an initial CT and if necessary, MRI will be used to further examine the volume of CSF leakage.
次要结局
未报告次要终点
研究者
研究点 (1)
Loading locations...
相似试验
Unknown
4 期
Kunxian for the Treatment of Rheumatoid ArthritisRheumatoid ArthritisNCT02764515Chinese SLE Treatment And Research Group428
Unknown
4 期
Treatment of Diffuse Large B Cell LymphomaDiffuse Large B Cell LymphomaNCT01949818Mingzhi Zhang120
已完成
4 期
Efficacy and Safety of Kunxian Capsule in Treatment Patients With Early Ankylosing SpondylitisTreatmentAnkylosing SpondylitisNCT00953979Gu Jieruo126
Unknown
4 期
Clinical Trial Scheme of Xinnaoning CapsuleChronic Stable Angina PectorisQi Stagnation and Blood Stasis SyndromeNCT03914131Beijing Duheng for Drug Evaluation and Research Co., Ltd. (DDER)240
已完成
不适用
Yinxingmihuan Oral Solution in Treatment of Chest Pain After PCIChronic Stable AnginaNCT06224582China National Center for Cardiovascular Diseases320